Pfizer Inc. (BKK:PFIZER19)
Thailand · Delayed Price · Currency is THB | Market Cap | 4.90T +17.0% |
| Revenue (ttm) | 2.08T +1.4% |
| Net Income | 246.18B -5.0% |
| EPS | 43.14 -5.1% |
| Shares Out | n/a |
| PE Ratio | 19.91 |
| Forward PE | 9.06 |
| Dividend | 0.68 (3.97%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 70,107 |
| Average Volume | 69,299 |
| Open | 17.20 |
| Previous Close | n/a |
| Day's Range | 17.20 - 17.50 |
| 52-Week Range | 15.10 - 18.70 |
| Beta | n/a |
| RSI | 47.51 |
| Earnings Date | May 5, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC
Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very c...
Pfizer CEO on AI-designed molecule, and race to use new tech
Pfizer CEO Albert Bourla says that company has reviewed its first AI-designed molecule. He says the company wants to be at the forefront of using artificial intellegence
3 Dividend Stocks for May 2026
This month's trio included a dividend aristocrat.
Pfizer Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong revenue and EPS growth, driven by robust performance in oncology, migraine, and vaccines. Legal settlements and pipeline progress support a high single-digit revenue CAGR post-2028, with disciplined capital allocation and cost management.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.
Why selling these 3 dividend stocks could be a mistake
Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income. Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy pro...
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched and acquired products showed growth. The pharmaceutical giant is looking to...
Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
Pfizer on Tuesday reported first-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis.
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bou...
How To Earn $500 A Month From Pfizer Stock Ahead Of Q1 Earnings
Pfizer Inc. (NYSE:PFE) will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per sh...
US FDA approves Pfizer, Arvinas' breast cancer drug
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' drug for a type of breast cancer.
Pfizer's blood cancer drug meets main goal in late-stage trial
Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment in patients who received at least one prior line of treatment.
Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapse...
Pfizer Stock Is Declining Today: What's Happening?
Pfizer Inc (NYSE:PFE) shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑med...
Pfizer secures deals to keep heart drug free of generic rivals until 2031
Pfizer said on Tuesday it has reached settlement agreements with three generic drugmakers over patent disputes tied to its heart drug, effectively extending its expiry until 2031 and buying...
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, re...
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood thinner through billionaire entrepreneur Mark Cuban's online pharmacy beginning April 27.
Pfizer Transcript: AGM 2026
The meeting highlighted strong 2025 financial results, robust R&D progress, and strategic acquisitions in oncology and obesity. All board nominees and management proposals passed, while a shareholder proposal for an independent chair was rejected. Commitment to dividend growth and AI-driven innovation was reaffirmed.
Pfizer Declares Second-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company's common stock, payable June 12, 2026, to ho...
Pfizer GLP-1 weight loss drug available for pre-order in China
Pfizer's GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market anal...
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual...
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according ...
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder can...